Specialised Therapeutics, an Australian biopharmaceutical company and Alimera’s distribution partner, to next seek national reimbursement ATLANTA , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription

  Second Quarter and Recent Company Highlights: Consolidated Net Revenue Up 2% Compared to Second Quarter 2018 International Net Revenue Up 21% Compared to Second Quarter 2018 UK’s NICE Provided Positive Opinion for Reimbursement of ILUVIEN ® in Non-Infectious Posterior Uveitis Indication Launched

ATLANTA , July 23, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN ® (fluocinolone acetonide

Conference Call to be held Tuesday, July 30, 2019 at 9:00am Eastern Time ATLANTA , July 22, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that it

ATLANTA , July 19, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces the appointment of John Snisarenko to its Board of Directors.

NICE decision is key milestone expanding access to patients in the United Kingdom ATLANTA , June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm Recently approved in Europe , ILUVIEN is expected to launch in certain EU countries during the second half of 2019 ATLANTA , June 06, 2019 (GLOBE NEWSWIRE) --

Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion ILUVIEN’s CONTINUOUS MICRODOSING™ delivery enables patients diagnosed with diabetic macular edema (DME) to maintain vision longer with fewer intra-ocular

ATLANTA , May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the

First Quarter and Recent Company Highlights: Global revenue up 34% versus Q1 2018 Regulatory approval obtained for ILUVIEN ® in 17 EU countries for the treatment of Non-Infectious Posterior Uveitis Samer Kaba , M.D. appointed to new position of Chief Medical Officer National pricing and